Cargando…
ZolpiMist™: a new formulation of zolpidem tartrate for the short-term treatment of insomnia in the US
ZolpiMist™ is an oral spray formulation of the hypnotic compound zolpidem that was approved by the US Food and Drug Administration in 2008 with an indication for the short-term treatment of insomnia characterized by difficulty with sleep initiation. It was developed by NovaDel Pharma, Inc. using the...
Autor principal: | Neubauer, David N |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3630936/ https://www.ncbi.nlm.nih.gov/pubmed/23616700 |
Ejemplares similares
-
Spectrophotometric methods for determination of zolpidem tartrate in tablet formulation
por: Chomwal, Rajiv, et al.
Publicado: (2010) -
Formulation and Evaluation of Controlled-Release Tablet of Zolpidem Tartrate by Melt Granulation Technique
por: Prajapati, Shailesh T., et al.
Publicado: (2011) -
Comparative pharmacokinetics of zolpidem tartrate in five ethnic populations of China
por: Guo, Tao, et al.
Publicado: (2014) -
Zolpidem modified-release in insomnia
por: Kirkwood, Cynthia, et al.
Publicado: (2007) -
Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder: A Phase 3 Randomized Clinical Trial
por: Rosenberg, Russell, et al.
Publicado: (2019)